{"id":745654,"date":"2018-10-18T05:57:00","date_gmt":"2018-10-18T05:57:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-in-combination-with-pfizers-inlyta-axitinib-significantly-improved-overall-survival-os-and-progression-free-survival-pfs-as-first-li\/"},"modified":"2025-11-07T01:26:59","modified_gmt":"2025-11-07T06:26:59","slug":"mercks-keytruda-pembrolizumab-in-combination-with-pfizers-inlyta-axitinib-significantly-improved-overall-survival-os-and-progression-free-survival-pfs-as-first-li","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-in-combination-with-pfizers-inlyta-axitinib-significantly-improved-overall-survival-os-and-progression-free-survival-pfs-as-first-li\/","title":{"rendered":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination with Pfizer\u2019s Inlyta\u00ae (axitinib) Significantly Improved Overall Survival (OS) and Progression-free Survival (PFS) as First-Line Therapy for Advanced or Metastatic Renal Cell Carcinoma"},"content":{"rendered":"<p class=\"bwalignc\">       KEYTRUDA is First Anti-PD-1 Therapy in Combination to Improve Both OS        and PFS in Advanced or Metastatic RCC, the Most Common Type of Kidney        Cancer     <\/p>\n<p class=\"bwalignc\">       Pivotal Phase 3 KEYNOTE-426 Trial Met Both Primary Endpoints; Data to        be Filed with Global Regulatory Authorities     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      announced today that the pivotal Phase 3 KEYNOTE-426 trial investigating<br \/>\n      KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab), Merck\u2019s anti-PD-1 therapy, in<br \/>\n      combination with Inlyta<sup>\u00ae<\/sup> (axitinib), Pfizer\u2019s tyrosine kinase<br \/>\n      inhibitor, met both primary endpoints of overall survival (OS) and<br \/>\n      progression-free survival (PFS) in the first-line treatment of advanced<br \/>\n      or metastatic renal cell carcinoma (RCC), the most common type of kidney<br \/>\n      cancer. Based on the first interim analysis by the independent Data<br \/>\n      Monitoring Committee (DMC), the KEYTRUDA plus Inlyta combination<br \/>\n      resulted in statistically significant and clinically meaningful<br \/>\n      improvements in OS and PFS, compared to sunitinib monotherapy. The study<br \/>\n      also met the key secondary endpoint of objective response rate (ORR),<br \/>\n      with significant improvements for the KEYTRUDA and Inlyta combination<br \/>\n      compared with sunitinib monotherapy. Results for OS, PFS and ORR were<br \/>\n      consistent regardless of PD-L1 expression and across all risk groups.<br \/>\n      The safety profile of KEYTRUDA and Inlyta in this trial was generally<br \/>\n      consistent with that observed in previously reported studies for each<br \/>\n      therapy. These results will be presented at an upcoming medical meeting<br \/>\n      and submitted to regulatory authorities worldwide.\n    <\/p>\n<p>\n      \u201cKEYTRUDA, in combination with the tyrosine kinase inhibitor Inlyta,<br \/>\n      resulted in significant and clinically meaningful improvements in<br \/>\n      overall survival, progression-free survival and objective response in<br \/>\n      this Phase 3 study. This marks the first time that combination treatment<br \/>\n      with an anti-PD-1 therapy has achieved the dual primary endpoints of<br \/>\n      overall survival and progression-free survival as first-line therapy in<br \/>\n      advanced renal cell carcinoma,\u201d said Dr. Roger M. Perlmutter, president,<br \/>\n      Merck Research Laboratories. \u201cFewer than 10 percent of those diagnosed<br \/>\n      with advanced renal cell carcinoma survive for five years, and hence<br \/>\n      there is significant need for improved therapies for this disease. We<br \/>\n      are very grateful to the investigators and patients for their<br \/>\n      involvement in this important study, the results of which will be filed<br \/>\n      with global regulatory authorities in the near future.\u201d\n    <\/p>\n<p>\n      <b>About KEYNOTE-426<\/b><br \/>\n<br \/>KEYNOTE-426 is a randomized, double-arm,<br \/>\n      Phase 3 trial (ClinicalTrials.gov, NCT02853331) evaluating the safety<br \/>\n      and efficacy of KEYTRUDA in combination with Inlyta as first-line<br \/>\n      treatment for advanced or metastatic RCC compared to sunitinib. The dual<br \/>\n      primary endpoints of the study were OS and PFS, and the key secondary<br \/>\n      endpoint was ORR. Additional secondary endpoints were disease control<br \/>\n      rate (DCR), number of participants who experienced or discontinued the<br \/>\n      study due to an adverse event (AE), duration of response (DOR), PFS at<br \/>\n      12, 18 and 24 months and OS at 12, 18 and 24 months. In the trial, 861<br \/>\n      patients were randomly assigned to receive KEYTRUDA 200 mg intravenously<br \/>\n      every three weeks plus Inlyta 5 mg orally twice daily for up to 24<br \/>\n      months, or sunitinib 50 mg orally once daily for four weeks followed by<br \/>\n      no treatment for two weeks, continuously.\n    <\/p>\n<p>\n      <b>About Renal Cell Carcinoma (RCC)<\/b><br \/>\n<br \/>Renal cell carcinoma (RCC)<br \/>\n      is by far the most common type of kidney cancer; about 9 out of 10<br \/>\n      kidney cancers are renal cell carcinomas. RCC is about twice as common<br \/>\n      in men as in women. Modifiable risk factors include smoking, obesity,<br \/>\n      workplace exposure to certain substances and high blood pressure. There<br \/>\n      are expected to be approximately 403,262 cases of kidney cancer<br \/>\n      diagnosed worldwide in 2018 and about 175,098 people will die from the<br \/>\n      disease. In the U.S. alone, there will be an estimated 63,340 new cases<br \/>\n      of kidney cancer diagnosed in 2018 and about 14,970 people will die from<br \/>\n      the disease\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Injection,<br \/>\n      100mg<\/b><br \/>\n<br \/>KEYTRUDA is an anti-PD-1 therapy that works by increasing<br \/>\n      the ability of the body\u2019s immune system to help detect and fight tumor<br \/>\n      cells. KEYTRUDA is a humanized monoclonal antibody that blocks the<br \/>\n      interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby<br \/>\n      activating T lymphocytes which may affect both tumor cells and healthy<br \/>\n      cells.\n    <\/p>\n<p>\n      Merck has the industry\u2019s largest immuno-oncology clinical research<br \/>\n      program. There are currently more than 850 trials studying KEYTRUDA<br \/>\n      across a wide variety of cancers and treatment settings. The KEYTRUDA<br \/>\n      clinical program seeks to understand the role of KEYTRUDA across cancers<br \/>\n      and the factors that may predict a patient\u2019s likelihood of benefitting<br \/>\n      from treatment with KEYTRUDA, including exploring several different<br \/>\n      biomarkers.\n    <\/p>\n<p>\n      <b>KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Indications and<br \/>\n      Dosing<\/b><br \/>\n<br \/>\n<i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma at a fixed dose of 200 mg every three weeks until<br \/>\n      disease progression or unacceptable toxicity.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is<br \/>\n      indicated for the first-line treatment of patients with metastatic<br \/>\n      nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is indicated for the first-line treatment<br \/>\n      of patients with metastatic non-small cell lung cancer (NSCLC) whose<br \/>\n      tumors have high PD-L1 expression [Tumor Proportion Score (TPS) \u226550%] as<br \/>\n      determined by an FDA-approved test, with no EGFR or ALK<i> <\/i>genomic<br \/>\n      tumor aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is also indicated for the treatment of<br \/>\n      patients with metastatic NSCLC whose tumors express PD-L1 (TPS \u22651%) as<br \/>\n      determined by an FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      In metastatic NSCLC, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA<br \/>\n      should be administered prior to chemotherapy when given on the same day.<br \/>\n      See also the Prescribing Information for pemetrexed and carboplatin or<br \/>\n      cisplatin, as appropriate.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In HNSCC, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Classical Hodgkin Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory classical Hodgkin lymphoma (cHL), or who have relapsed<br \/>\n      after three or more prior lines of therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. In adults with cHL, KEYTRUDA is administered at a<br \/>\n      fixed dose of 200 mg every three weeks until disease progression or<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression. In pediatric patients with cHL, KEYTRUDA is administered at<br \/>\n      a dose of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until<br \/>\n      disease progression or unacceptable toxicity, or up to 24 months in<br \/>\n      patients without disease progression.\n    <\/p>\n<p>\n      <i>Primary Mediastinal Large B-Cell Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory primary mediastinal large B-cell lymphoma (PMBCL), or<br \/>\n      who have relapsed after 2 or more prior lines of therapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in confirmatory trials. KEYTRUDA is not recommended for<br \/>\n      the treatment of patients with PMBCL who require urgent cytoreductive<br \/>\n      therapy.\n    <\/p>\n<p>\n      In adults with PMBCL, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression. In pediatric<br \/>\n      patients with PMBCL, KEYTRUDA is administered at a dose of 2 mg\/kg (up<br \/>\n      to a maximum of 200 mg) every three weeks until disease progression or<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression.\n    <\/p>\n<p>\n      <i>Urothelial Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma (mUC) who are not eligible<br \/>\n      for cisplatin-containing chemotherapy and whose tumors express PD-L1<br \/>\n      [Combined Positive Score (CPS) \u226510] as determined by an FDA-approved<br \/>\n      test, or in patients who are not eligible for any platinum-containing<br \/>\n      chemotherapy regardless of PD-L1 status. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and duration of<br \/>\n      response. Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials.\n    <\/p>\n<p>\n      KEYTRUDA is also indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma (mUC) who have disease<br \/>\n      progression during or following platinum-containing chemotherapy or<br \/>\n      within 12 months of neoadjuvant or adjuvant treatment with<br \/>\n      platinum-containing chemotherapy.\n    <\/p>\n<p>\n      In locally advanced or metastatic urothelial carcinoma, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Microsatellite Instability-High (MSI-H) Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with unresectable or metastatic microsatellite instability-high (MSI-H)<br \/>\n      or mismatch repair deficient (dMMR)\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        solid tumors that have progressed following prior treatment and who<br \/>\n        have no satisfactory alternative treatment options, or\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        colorectal cancer that has progressed following treatment with<br \/>\n        fluoropyrimidine, oxaliplatin, and irinotecan.\n      <\/li>\n<\/ul>\n<p>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The safety and<br \/>\n      effectiveness of KEYTRUDA in pediatric patients with MSI-H central<br \/>\n      nervous system cancers have not been established.\n    <\/p>\n<p>\n      In adult patients with MSI-H cancer, KEYTRUDA is administered at a fixed<br \/>\n      dose of 200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression. In<br \/>\n      children with MSI-H cancer, KEYTRUDA is administered at a dose of 2<br \/>\n      mg\/kg (up to a maximum of 200 mg) every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Gastric Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent<br \/>\n      locally advanced or metastatic gastric or gastroesophageal junction<br \/>\n      (GEJ) adenocarcinoma whose tumors express PD-L1 [Combined Positive Score<br \/>\n      (CPS) \u22651] as determined by an FDA-approved test, with disease<br \/>\n      progression on or after two or more prior lines of therapy including<br \/>\n      fluoropyrimidine- and platinum-containing chemotherapy and if<br \/>\n      appropriate, HER2\/neu-targeted therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. The recommended dose of KEYTRUDA is a fixed dose of<br \/>\n      200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Cervical Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic cervical cancer with disease progression on or after<br \/>\n      chemotherapy whose tumors express PD-L1 (CPS \u22651) as determined by an<br \/>\n      FDA-approved test. This indication is approved under accelerated<br \/>\n      approval based on tumor response rate and durability of response.<br \/>\n      Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials. The recommended dose of KEYTRUDA is a fixed dose of 200 mg every<br \/>\n      three weeks until disease progression, unacceptable toxicity or up to 24<br \/>\n      months in patients without disease progression.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b>\n    <\/p>\n<p>\n      <b>Immune-Mediated Pneumonitis<\/b><br \/>\n<br \/>KEYTRUDA can cause<br \/>\n      immune-mediated pneumonitis, including fatal cases. Pneumonitis occurred<br \/>\n      in 3.4% (94\/2799) of patients receiving KEYTRUDA, including Grade 1<br \/>\n      (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%), and occurred more<br \/>\n      frequently in patients with a history of prior thoracic radiation (6.9%)<br \/>\n      compared to those without (2.9%). Monitor patients for signs and<br \/>\n      symptoms of pneumonitis. Evaluate suspected pneumonitis with<br \/>\n      radiographic imaging. Administer corticosteroids for Grade 2 or greater<br \/>\n      pneumonitis. Withhold KEYTRUDA for Grade 2; permanently discontinue for<br \/>\n      Grade 3 or 4 or recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      <b>Immune-Mediated Colitis<\/b><br \/>\n<br \/>KEYTRUDA can cause immune-mediated<br \/>\n      colitis. Colitis occurred in 1.7% (48\/2799) of patients receiving<br \/>\n      KEYTRUDA, including Grade 2 (0.4%), 3 (1.1%), and 4 (&lt;0.1%). Monitor<br \/>\n      patients for signs and symptoms of colitis. Administer corticosteroids<br \/>\n      for Grade 2 or greater colitis. Withhold KEYTRUDA for Grade 2 or 3;<br \/>\n      permanently discontinue for Grade 4 colitis.\n    <\/p>\n<p>\n      <b>Immune-Mediated Hepatitis<\/b><br \/>\n<br \/>KEYTRUDA can cause immune-mediated<br \/>\n      hepatitis. Hepatitis occurred in 0.7% (19\/2799) of patients receiving<br \/>\n      KEYTRUDA, including Grade 2 (0.1%), 3 (0.4%), and 4 (&lt;0.1%). Monitor<br \/>\n      patients for changes in liver function. Administer corticosteroids for<br \/>\n      Grade 2 or greater hepatitis and, based on severity of liver enzyme<br \/>\n      elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      <b>Immune-Mediated Endocrinopathies<\/b><br \/>\n<br \/>KEYTRUDA can cause<br \/>\n      hypophysitis, thyroid disorders, and type 1 diabetes mellitus.<br \/>\n      Hypophysitis occurred in 0.6% (17\/2799) of patients, including Grade 2<br \/>\n      (0.2%), 3 (0.3%), and 4 (&lt;0.1%). Hypothyroidism occurred in 8.5%<br \/>\n      (237\/2799) of patients, including Grade 2 (6.2%) and 3 (0.1%). The<br \/>\n      incidence of new or worsening hypothyroidism was higher in patients with<br \/>\n      HNSCC occurring in 15% (28\/192) of patients. Hyperthyroidism occurred in<br \/>\n      3.4% (96\/2799) of patients, including Grade 2 (0.8%) and 3 (0.1%), and<br \/>\n      thyroiditis occurred in 0.6% (16\/2799) of patients, including Grade 2<br \/>\n      (0.3%). Type 1 diabetes mellitus, including diabetic ketoacidosis,<br \/>\n      occurred in 0.2% (6\/2799) of patients.\n    <\/p>\n<p>\n      Monitor patients for signs and symptoms of hypophysitis (including<br \/>\n      hypopituitarism and adrenal insufficiency), thyroid function (prior to<br \/>\n      and periodically during treatment), and hyperglycemia. For hypophysitis,<br \/>\n      administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2 and withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis. Administer hormone replacement for<br \/>\n      hypothyroidism and manage hyperthyroidism with thionamides and<br \/>\n      beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for Grade<br \/>\n      3 or 4 hyperthyroidism. Administer insulin for type 1 diabetes, and<br \/>\n      withhold KEYTRUDA and administer anti-hyperglycemics in patients with<br \/>\n      severe hyperglycemia.\n    <\/p>\n<p>\n      <b>Immune-Mediated Nephritis and Renal Dysfunction<\/b><br \/>\n<br \/>KEYTRUDA can<br \/>\n      cause immune-mediated nephritis. Nephritis occurred in 0.3% (9\/2799) of<br \/>\n      patients receiving KEYTRUDA, including Grade 2 (0.1%), 3 (0.1%), and 4<br \/>\n      (&lt;0.1%) nephritis. Nephritis occurred in 1.7% (7\/405) of patients<br \/>\n      receiving KEYTRUDA in combination with pemetrexed and platinum<br \/>\n      chemotherapy. Monitor patients for changes in renal function. Administer<br \/>\n      corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for<br \/>\n      Grade 2; permanently discontinue for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      <b>Immune-Mediated Skin Reactions<\/b><br \/>\n<br \/>Immune-mediated rashes,<br \/>\n      including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis<br \/>\n      (TEN) (some cases with fatal outcome), exfoliative dermatitis, and<br \/>\n      bullous pemphigoid, can occur. Monitor patients for suspected severe<br \/>\n      skin reactions and based on the severity of the adverse reaction,<br \/>\n      withhold or permanently discontinue KEYTRUDA and administer<br \/>\n      corticosteroids. For signs or symptoms of SJS or TEN, withhold KEYTRUDA<br \/>\n      and refer the patient for specialized care for assessment and treatment.<br \/>\n      If SJS or TEN is confirmed, permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      <b>Other Immune-Mediated Adverse Reactions<\/b><br \/>\n<br \/>Immune-mediated<br \/>\n      adverse reactions, which may be severe or fatal, can occur in any organ<br \/>\n      system or tissue in patients receiving KEYTRUDA and may also occur after<br \/>\n      discontinuation of treatment. For suspected immune-mediated adverse<br \/>\n      reactions, ensure adequate evaluation to confirm etiology or exclude<br \/>\n      other causes. Based on the severity of the adverse reaction, withhold<br \/>\n      KEYTRUDA and administer corticosteroids. Upon improvement to Grade 1 or<br \/>\n      less, initiate corticosteroid taper and continue to taper over at least<br \/>\n      1 month. Based on limited data from clinical studies in patients whose<br \/>\n      immune-related adverse reactions could not be controlled with<br \/>\n      corticosteroid use, administration of other systemic immunosuppressants<br \/>\n      can be considered. Resume KEYTRUDA when the adverse reaction remains at<br \/>\n      Grade 1 or less following corticosteroid taper. Permanently discontinue<br \/>\n      KEYTRUDA for any Grade 3 immune-mediated adverse reaction that recurs<br \/>\n      and for any life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia<br \/>\n      gravis, vasculitis, pancreatitis, hemolytic anemia, sarcoidosis, and<br \/>\n      encephalitis. In addition, myelitis and myocarditis were reported in<br \/>\n      other clinical trials and postmarketing use.\n    <\/p>\n<p>\n      Treatment with KEYTRUDA may increase the risk of rejection in solid<br \/>\n      organ transplant recipients. Consider the benefit of treatment vs the<br \/>\n      risk of possible organ rejection in these patients.\n    <\/p>\n<p>\n      <b>Infusion-Related Reactions<\/b><br \/>\n<br \/>KEYTRUDA can cause severe or<br \/>\n      life-threatening infusion-related reactions, including hypersensitivity<br \/>\n      and anaphylaxis, which have been reported in 0.2% (6\/2799) of patients.<br \/>\n      Monitor patients for signs and symptoms of infusion-related reactions.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      <b>Complications of Allogenic Hematopoietic Stem Cell Transplantation<br \/>\n      (HSCT)<\/b><br \/>\n<br \/>Immune-mediated complications, including fatal events,<br \/>\n      occurred in patients who underwent allogeneic HSCT after treatment with<br \/>\n      KEYTRUDA. Of 23 patients with cHL who proceeded to allogeneic HSCT after<br \/>\n      KEYTRUDA, 6 developed graft-versus-host disease (GVHD) (one fatal case)<br \/>\n      and 2 developed severe hepatic veno-occlusive disease (VOD) after<br \/>\n      reduced-intensity conditioning (one fatal case). Cases of fatal<br \/>\n      hyperacute GVHD after allogeneic HSCT have also been reported in<br \/>\n      patients with lymphoma who received a PD-1 receptor\u2013blocking antibody<br \/>\n      before transplantation. Follow patients closely for early evidence of<br \/>\n      transplant-related complications such as hyperacute graft-versus-host<br \/>\n      disease (GVHD), Grade 3 to 4 acute GVHD, steroid-requiring febrile<br \/>\n      syndrome, hepatic veno-occlusive disease (VOD), and other<br \/>\n      immune-mediated adverse reactions.\n    <\/p>\n<p>\n      In patients with a history of allogeneic HSCT, acute GVHD (including<br \/>\n      fatal GVHD), has been reported after treatment with KEYTRUDA. Patients<br \/>\n      who experienced GVHD after their transplant procedure may be at<br \/>\n      increased risk for GVHD after KEYTRUDA. Consider the benefit of KEYTRUDA<br \/>\n      vs the risk of GVHD in these patients.\n    <\/p>\n<p>\n      <b>Increased Mortality in Patients with Multiple Myeloma<\/b><br \/>\n<br \/>In<br \/>\n      clinical trials in patients with multiple myeloma, the addition of<br \/>\n      KEYTRUDA to a thalidomide analogue plus dexamethasone resulted in<br \/>\n      increased mortality. Treatment of these patients with a PD-1 or PD-L1<br \/>\n      blocking antibody in this combination is not recommended outside of<br \/>\n      controlled clinical trials.\n    <\/p>\n<p>\n      <b>Embryofetal Toxicity<\/b><br \/>\n<br \/>Based on its mechanism of action,<br \/>\n      KEYTRUDA can cause fetal harm when administered to a pregnant woman. If<br \/>\n      used during pregnancy, or if the patient becomes pregnant during<br \/>\n      treatment, apprise the patient of the potential hazard to a fetus.<br \/>\n      Advise females of reproductive potential to use highly effective<br \/>\n      contraception during treatment and for 4 months after the last dose of<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      <b>Adverse Reactions<\/b><br \/>\n<br \/>In KEYNOTE-006, KEYTRUDA was discontinued<br \/>\n      due to adverse reactions in 9% of 555 patients with advanced melanoma;<br \/>\n      adverse reactions leading to permanent discontinuation in more than one<br \/>\n      patient were colitis (1.4%), autoimmune hepatitis (0.7%), allergic<br \/>\n      reaction (0.4%), polyneuropathy (0.4%), and cardiac failure (0.4%). The<br \/>\n      most common adverse reactions (\u226520%) with KEYTRUDA were fatigue (28%),<br \/>\n      diarrhea (26%), rash (24%), and nausea (21%).\n    <\/p>\n<p>\n      In KEYNOTE-189, when KEYTRUDA was administered with pemetrexed and<br \/>\n      platinum chemotherapy in metastatic nonsquamous NSCLC, KEYTRUDA was<br \/>\n      discontinued due to adverse reactions in 20% of 405 patients. The most<br \/>\n      common adverse reactions resulting in permanent discontinuation of<br \/>\n      KEYTRUDA were pneumonitis (3%) and acute kidney injury (2%). The most<br \/>\n      common adverse reactions (\u226520%) with KEYTRUDA were nausea (56%), fatigue<br \/>\n      (56%), constipation (35%), diarrhea (31%), decreased appetite (28%),<br \/>\n      rash (25%), vomiting (24%), cough (21%), dyspnea (21%), and pyrexia<br \/>\n      (20%).\n    <\/p>\n<p>\n      In KEYNOTE-010, KEYTRUDA monotherapy was discontinued due to adverse<br \/>\n      reactions in 8% of 682 patients with metastatic NSCLC. The most common<br \/>\n      adverse event resulting in permanent discontinuation of KEYTRUDA was<br \/>\n      pneumonitis (1.8%). The most common adverse reactions (\u226520%) were<br \/>\n      decreased appetite (25%), fatigue (25%), dyspnea (23%), and nausea (20%).\n    <\/p>\n<p>\n      In KEYNOTE-012, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      17% of 192 patients with HNSCC. Serious adverse reactions occurred in<br \/>\n      45% of patients. The most frequent serious adverse reactions reported in<br \/>\n      at least 2% of patients were pneumonia, dyspnea, confusional state,<br \/>\n      vomiting, pleural effusion, and respiratory failure. The most common<br \/>\n      adverse reactions (\u226520%) were fatigue, decreased appetite, and dyspnea.<br \/>\n      Adverse reactions occurring in patients with HNSCC were generally<br \/>\n      similar to those occurring in patients with melanoma or NSCLC, with the<br \/>\n      exception of increased incidences of facial edema and new or worsening<br \/>\n      hypothyroidism.\n    <\/p>\n<p>\n      In KEYNOTE-087, KEYTRUDA was discontinued due to adverse reactions in 5%<br \/>\n      of 210 patients with cHL. Serious adverse reactions occurred in 16% of<br \/>\n      patients; those \u22651% included pneumonia, pneumonitis, pyrexia, dyspnea,<br \/>\n      GVHD, and herpes zoster. Two patients died from causes other than<br \/>\n      disease progression; one from GVHD after subsequent allogeneic HSCT and<br \/>\n      one from septic shock. The most common adverse reactions (\u226520%) were<br \/>\n      fatigue (26%), pyrexia (24%), cough (24%), musculoskeletal pain (21%),<br \/>\n      diarrhea (20%), and rash (20%).\n    <\/p>\n<p>\n      In KEYNOTE-170, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 53 patients with PMBCL. Serious adverse reactions occurred in 26% of<br \/>\n      patients and included arrhythmia (4%), cardiac tamponade (2%),<br \/>\n      myocardial infarction (2%), pericardial effusion (2%), and pericarditis<br \/>\n      (2%). Six (11%) patients died within 30 days of start of treatment. The<br \/>\n      most common adverse reactions (\u226520%) were musculoskeletal pain (30%),<br \/>\n      upper respiratory tract infection and pyrexia (28% each), cough (26%),<br \/>\n      fatigue (23%), and dyspnea (21%).\n    <\/p>\n<p>\n      In KEYNOTE-052, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      11% of 370 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. Serious adverse reactions occurred in 42% of patients; those<br \/>\n      \u22652% were urinary tract infection, hematuria, acute kidney injury,<br \/>\n      pneumonia, and urosepsis. The most common adverse reactions (\u226520%) were<br \/>\n      fatigue (38%), musculoskeletal pain (24%), decreased appetite (22%),<br \/>\n      constipation (21%), rash (21%), and diarrhea (20%).\n    <\/p>\n<p>\n      In KEYNOTE-045, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 266 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. The most common adverse reaction resulting in permanent<br \/>\n      discontinuation of KEYTRUDA was pneumonitis (1.9%). Serious adverse<br \/>\n      reactions occurred in 39% of KEYTRUDA-treated patients; those \u22652% were<br \/>\n      urinary tract infection, pneumonia, anemia, and pneumonitis. The most<br \/>\n      common adverse reactions (\u226520%) in patients who received KEYTRUDA were<br \/>\n      fatigue (38%), musculoskeletal pain (32%), pruritus (23%), decreased<br \/>\n      appetite (21%), nausea (21%), and rash (20%).\n    <\/p>\n<p>\n      In KEYNOTE-158, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 98 patients with recurrent or metastatic cervical cancer. Serious<br \/>\n      adverse reactions occurred in 39% of patients receiving KEYTRUDA; the<br \/>\n      most frequent included anemia (7%), fistula, hemorrhage, and infections<br \/>\n      [except urinary tract infections] (4.1% each). The most common adverse<br \/>\n      reactions (\u226520%) were fatigue (43%), musculoskeletal pain (27%),<br \/>\n      diarrhea (23%), pain and abdominal pain (22% each), and decreased<br \/>\n      appetite (21%).\n    <\/p>\n<p>\n      <b>Lactation<\/b><br \/>\n<br \/>It is not known whether KEYTRUDA is excreted in<br \/>\n      human milk. Because many drugs are excreted in human milk, instruct<br \/>\n      women to discontinue nursing during treatment with KEYTRUDA and for 4<br \/>\n      months after the final dose.\n    <\/p>\n<p>\n      <b>Pediatric Use<\/b><br \/>\n<br \/>There is limited experience in pediatric<br \/>\n      patients. In a study in 40 pediatric patients with advanced melanoma,<br \/>\n      lymphoma, or PD-L1\u2013positive advanced, relapsed, or refractory solid<br \/>\n      tumors, the safety profile was similar to that seen in adults treated<br \/>\n      with KEYTRUDA. Toxicities that occurred at a higher rate (\u226515%<br \/>\n      difference) in these patients when compared to adults under 65 years of<br \/>\n      age were fatigue (45%), vomiting (38%), abdominal pain (28%),<br \/>\n      hypertransaminasemia (28%), and hyponatremia (18%).\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b><br \/>\n<br \/>Our goal is to translate<br \/>\n      breakthrough science into innovative oncology medicines to help people<br \/>\n      with cancer worldwide. At Merck, the potential to bring new hope to<br \/>\n      people with cancer drives our purpose and supporting accessibility to<br \/>\n      our cancer medicines is our commitment. As part of our focus on cancer,<br \/>\n      Merck is committed to exploring the potential of immuno-oncology with<br \/>\n      one of the largest development programs in the industry across more than<br \/>\n      30 tumor types. We also continue to strengthen our portfolio through<br \/>\n      strategic acquisitions and are prioritizing the development of several<br \/>\n      promising oncology candidates with the potential to improve the<br \/>\n      treatment of advanced cancers. For more information about our oncology<br \/>\n      clinical trials, visit <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/clinicaltrials\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b><br \/>\n<br \/>For more than a century, Merck, a leading global<br \/>\n      biopharmaceutical company known as MSD outside of the United States and<br \/>\n      Canada, has been inventing for life, bringing forward medicines and<br \/>\n      vaccines for many of the world\u2019s most challenging diseases. Through our<br \/>\n      prescription medicines, vaccines, biologic therapies and animal health<br \/>\n      products, we work with customers and operate in more than 140 countries<br \/>\n      to deliver innovative health solutions. We also demonstrate our<br \/>\n      commitment to increasing access to health care through far-reaching<br \/>\n      policies, programs and partnerships. Today, Merck continues to be at the<br \/>\n      forefront of research to advance the prevention and treatment of<br \/>\n      diseases that threaten people and communities around the world &#8211;<br \/>\n      including cancer, cardio-metabolic diseases, emerging animal diseases,<br \/>\n      Alzheimer\u2019s disease and infectious diseases including HIV and Ebola. For<br \/>\n      more information, visit&nbsp;<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a>&nbsp;and&nbsp;connect<br \/>\n      with us on <a href=\"https:\/\/twitter.com\/Merck\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"https:\/\/www.facebook.com\/MerckInvents\/\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"https:\/\/www.instagram.com\/merck\/\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"https:\/\/www.youtube.com\/user\/Merck\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"https:\/\/www.linkedin.com\/company\/merck\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b><br \/>\n<br \/>This<br \/>\n      news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the \u201ccompany\u201d)<br \/>\n      includes \u201cforward-looking statements\u201d within the meaning of the safe<br \/>\n      harbor provisions of the U.S. Private Securities Litigation Reform Act<br \/>\n      of 1995. These statements are based upon the current beliefs and<br \/>\n      expectations of the company\u2019s management and are subject to significant<br \/>\n      risks and uncertainties. There can be no guarantees with respect to<br \/>\n      pipeline products that the products will receive the necessary<br \/>\n      regulatory approvals or that they will prove to be commercially<br \/>\n      successful. If underlying assumptions prove inaccurate or risks or<br \/>\n      uncertainties materialize, actual results may differ materially from<br \/>\n      those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2017 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;and<\/b>\n    <\/p>\n<p>\n      <b>Medication Guide for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20181018005409r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       For Merck<br \/>Media Contacts:<br \/>Pamela Eisele<br \/>(267) 305-3558<br \/>or<br \/>Kristen        Drake<br \/>(908) 334-4688<br \/>or<br \/>Investor Contacts:<br \/>Teri Loxam<br \/>(908)        740-1986<br \/>or<br \/>Peter Dannenbaum<br \/>(908) 740-1037     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-426 trial investigating KEYTRUDA \u00ae (pembrolizumab), Merck\u2019s anti-PD-1 therapy, in combination with Inlyta \u00ae (axitinib), Pfizer\u2019s tyrosine kinase inhibitor, met both primary endpoints of overall survival (OS) and progression-free survival (PFS) in the first-line treatment of advanced or metastatic renal cell carcinoma (RCC), the most common type of kidney cancer. Based on the first interim analysis by the independent Data Monitoring Committee (DMC), the KEYTRUDA plus Inlyta combination resulted in statistically significant and clinically meaningful improvements in OS and PFS, compared to sunitinib monotherapy. The study also met the key secondary endpoint of objective response rate (ORR), with significant improvements for the KEYTRUDA and Inlyta combination compared with sunitinib monotherapy. Results for OS, PFS and ORR were consistent regardless of PD-L1 expression<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,138,289,56],"class_list":["post-745654","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology-newsroom","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination with Pfizer\u2019s Inlyta\u00ae (axitinib) Significantly Improved Overall Survival (OS) and Progression-free Survival (PFS) as First-Line Therapy for Advanced or Metastatic Renal Cell Carcinoma - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-in-combination-with-pfizers-inlyta-axitinib-significantly-improved-overall-survival-os-and-progression-free-survival-pfs-as-first-li\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination with Pfizer\u2019s Inlyta\u00ae (axitinib) Significantly Improved Overall Survival (OS) and Progression-free Survival (PFS) as First-Line Therapy for Advanced or Metastatic Renal Cell Carcinoma - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-426 trial investigating KEYTRUDA \u00ae (pembrolizumab), Merck\u2019s anti-PD-1 therapy, in combination with Inlyta \u00ae (axitinib), Pfizer\u2019s tyrosine kinase inhibitor, met both primary endpoints of overall survival (OS) and progression-free survival (PFS) in the first-line treatment of advanced or metastatic renal cell carcinoma (RCC), the most common type of kidney cancer. Based on the first interim analysis by the independent Data Monitoring Committee (DMC), the KEYTRUDA plus Inlyta combination resulted in statistically significant and clinically meaningful improvements in OS and PFS, compared to sunitinib monotherapy. The study also met the key secondary endpoint of objective response rate (ORR), with significant improvements for the KEYTRUDA and Inlyta combination compared with sunitinib monotherapy. Results for OS, PFS and ORR were consistent regardless of PD-L1 expression\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-in-combination-with-pfizers-inlyta-axitinib-significantly-improved-overall-survival-os-and-progression-free-survival-pfs-as-first-li\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"21 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-in-combination-with-pfizers-inlyta-axitinib-significantly-improved-overall-survival-os-and-progression-free-survival-pfs-as-first-li\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-in-combination-with-pfizers-inlyta-axitinib-significantly-improved-overall-survival-os-and-progression-free-survival-pfs-as-first-li\\\/\",\"name\":\"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination with Pfizer\u2019s Inlyta\u00ae (axitinib) Significantly Improved Overall Survival (OS) and Progression-free Survival (PFS) as First-Line Therapy for Advanced or Metastatic Renal Cell Carcinoma - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2018-10-18T05:57:00+00:00\",\"dateModified\":\"2025-11-07T06:26:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-in-combination-with-pfizers-inlyta-axitinib-significantly-improved-overall-survival-os-and-progression-free-survival-pfs-as-first-li\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-in-combination-with-pfizers-inlyta-axitinib-significantly-improved-overall-survival-os-and-progression-free-survival-pfs-as-first-li\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-in-combination-with-pfizers-inlyta-axitinib-significantly-improved-overall-survival-os-and-progression-free-survival-pfs-as-first-li\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination with Pfizer\u2019s Inlyta\u00ae (axitinib) Significantly Improved Overall Survival (OS) and Progression-free Survival (PFS) as First-Line Therapy for Advanced or Metastatic Renal Cell Carcinoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination with Pfizer\u2019s Inlyta\u00ae (axitinib) Significantly Improved Overall Survival (OS) and Progression-free Survival (PFS) as First-Line Therapy for Advanced or Metastatic Renal Cell Carcinoma - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-in-combination-with-pfizers-inlyta-axitinib-significantly-improved-overall-survival-os-and-progression-free-survival-pfs-as-first-li\/","og_locale":"en_US","og_type":"article","og_title":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination with Pfizer\u2019s Inlyta\u00ae (axitinib) Significantly Improved Overall Survival (OS) and Progression-free Survival (PFS) as First-Line Therapy for Advanced or Metastatic Renal Cell Carcinoma - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-426 trial investigating KEYTRUDA \u00ae (pembrolizumab), Merck\u2019s anti-PD-1 therapy, in combination with Inlyta \u00ae (axitinib), Pfizer\u2019s tyrosine kinase inhibitor, met both primary endpoints of overall survival (OS) and progression-free survival (PFS) in the first-line treatment of advanced or metastatic renal cell carcinoma (RCC), the most common type of kidney cancer. Based on the first interim analysis by the independent Data Monitoring Committee (DMC), the KEYTRUDA plus Inlyta combination resulted in statistically significant and clinically meaningful improvements in OS and PFS, compared to sunitinib monotherapy. The study also met the key secondary endpoint of objective response rate (ORR), with significant improvements for the KEYTRUDA and Inlyta combination compared with sunitinib monotherapy. Results for OS, PFS and ORR were consistent regardless of PD-L1 expression","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-in-combination-with-pfizers-inlyta-axitinib-significantly-improved-overall-survival-os-and-progression-free-survival-pfs-as-first-li\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:59+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"21 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-in-combination-with-pfizers-inlyta-axitinib-significantly-improved-overall-survival-os-and-progression-free-survival-pfs-as-first-li\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-in-combination-with-pfizers-inlyta-axitinib-significantly-improved-overall-survival-os-and-progression-free-survival-pfs-as-first-li\/","name":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination with Pfizer\u2019s Inlyta\u00ae (axitinib) Significantly Improved Overall Survival (OS) and Progression-free Survival (PFS) as First-Line Therapy for Advanced or Metastatic Renal Cell Carcinoma - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2018-10-18T05:57:00+00:00","dateModified":"2025-11-07T06:26:59+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-in-combination-with-pfizers-inlyta-axitinib-significantly-improved-overall-survival-os-and-progression-free-survival-pfs-as-first-li\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-in-combination-with-pfizers-inlyta-axitinib-significantly-improved-overall-survival-os-and-progression-free-survival-pfs-as-first-li\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-in-combination-with-pfizers-inlyta-axitinib-significantly-improved-overall-survival-os-and-progression-free-survival-pfs-as-first-li\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination with Pfizer\u2019s Inlyta\u00ae (axitinib) Significantly Improved Overall Survival (OS) and Progression-free Survival (PFS) as First-Line Therapy for Advanced or Metastatic Renal Cell Carcinoma"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"05f3f7a1-2165-439f-b40e-243d7b6a1fe5","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Mercks-KEYTRUDA-pembrolizumab-in-Combination-with-Pfizers-Inlyta-axitinib-Significantly-Improved-Overall-Survival-OS-and-Progression--RFMZU.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745654","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745654\/revisions"}],"predecessor-version":[{"id":3675002,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745654\/revisions\/3675002"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745654"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745654"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}